Background and Objective Unplanned pregnancies can lead to poorer maternal and child health outcomes. The Australian Therapeutic Goods Administration committee rejected reclassifying a range of oral contraceptive pills (OCPs) from prescription to pharmacist-only medicines in 2015, mainly based on safety concerns. Improving access to OCPs may encourage some women to use contraceptives or switch from other contraceptive methods. However, some adverse events may increase and some women may stop using condoms, increasing their risk of sexually transmitted infections. This study aimed to estimate the cost effectiveness of reclassifying OCPs from prescription to pharmacist-only. Perspective Healthcare system. Setting Australian primary care. Methods A Markov model was used to synthesise data from a variety of sources. The model included all Australian women aged 15-49 years (N = 5,644,701). The time horizon was 35 years. Contraceptive use before reclassification was estimated using data from the Household, Income and Labour Dynamics in Australia (HILDA) survey, while survey data informed use after reclassification. Health outcomes included pregnancies, pregnancy outcomes (live birth, miscarriage, stillbirth, ectopic pregnancy and abortion), sexually transmitted infections, adverse events (venous thromboembolism, depression, myocardial infarction and stroke), ovarian cancer cases and quality-adjusted life-years. Costs included those related to general practitioner and specialist consultations, contraceptives and other medicines, pharmacist time, hospitalisations and adverse events. All costs were reported in 2016 Australian Dollars. A 5% discount rate was applied to health outcomes and costs. Results Reclassifying OCPs resulted in 85.70 million quality-adjusted life-years experienced and costs of $46,910.14 million over 35 years, vs. 85.68 million quality-adjusted life-years experienced and costs of $50,274.95 million with OCPs remaining prescription-only. Thus, reclassifying OCPs was more effective and cost saving. However, a sensitivity analysis found that more research on the probability of pregnancy in women not using contraception and not trying to conceive is needed. Conclusion Reclassifying OCPs is likely to be considered cost effective by Australian decision makers.
Introduction
Unintended pregnancies can have an adverse impact on the physical and psychosocial health, well-being and quality of life for women, and compromise their education and employment outcomes [1, 2] . Unplanned infants are more likely to be faced with risky maternal behaviours, poor antenatal care, reduced nutrition and a shorter breastfeeding duration [3] [4] [5] [6] . Approximately 55.1% of Australian women aged 15-49 years use contraception, most commonly the oral contraceptive pill [OCP] (33.1%), followed by condoms (24.5%) [7] . Regardless, 26% of women have experienced an unplanned pregnancy [6] .
Key Points for Decision Makers
Reclassifying the oral contraceptive pill from prescription-only to pharmacist-only is likely to result in net health gains and be cost saving, even after accounting for a broad range of adverse events and sexually transmitted infections.
Economic modelling of medicine reclassification decisions has several advantages compared with deliberation alone or a multi-criteria analysis, including: synthesising evidence; aggregating safety concerns and health benefits into a single measure (quality adjusted life years); and considering healthcare resource use.
Sensitivity analysis can be used to identify areas needing further research and exploring different regulatory scenarios.
hormonal contraceptives without a prescription from specially trained pharmacists following the completion of a screening tool [13, 14] . Non-prescription medicine supply (e.g. vaccinations) through specially trained pharmacists using screening tools is becoming increasingly common, and enables prescription to non-prescription reclassification [15, 16] .
Economic modelling of medicine reclassification decisions has several advantages compared with deliberation, currently used by the TGA committee, or a multi-criteria analysis, proposed by Brass et al. [17] . These include: synthesising evidence; aggregating safety concerns and health benefits into a single measure (quality-adjusted life-years, QALYs); considering healthcare resource use; and identifying areas needing further research and exploring different regulatory scenarios through a sensitivity analysis.
This study used economic modelling to estimate the cost effectiveness of reclassifying OCPs to pharmacist-only (supply without a prescription) compared with remaining prescription-only in Australia, thus demonstrating the advantages of using economic modelling to help with reclassification decisions. Pharmacists can only supply a pharmacistonly OCP if eligibility criteria are met, which are assessed using a tool (an OCP Questionnaire) at each request for pharmacist-only OCPs. One criterion is that the woman has previously been prescribed an OCP, similar to New Zealand [18, 19] .
Methods
A Markov model was constructed to compare the current situation where prescription-only OCPs are available to a scenario where OCPs are reclassified to pharmacist-only (see Figs. 1, 2, 3) . Four economic evaluations of OCP reclassification have previously been conducted [20] [21] [22] [23] . None involved a decision tree or Markov model, and all considered only a 1-year time horizon or did not report a time horizon. Consequently, the model structure was informed by a review of economic evaluations comparing multiple contraceptive methods, particularly Sonnenberg et al. [24] The model included all Australian women aged 15-49 years (N = 5,644,701). These ages reflect the median age of sexual debut (17 years) and the median age of sterility (44.7 years), and thus likely OCP users [25, 26] . In Australia, there is no legal age limit to access the emergency contraception pill as a pharmacist-only medicine, except in Queensland (women must be aged ≥ 16 years) [27] . Any lower or upper age limits to accessing pharmacist-only OCPs could be specified through the OCP Questionnaire (e.g. ≥ 16 years of age or < 40 years of age).
In Australia, OCPs are available by prescription-only, which creates a barrier to accessing OCPs. A survey of women's attitudes towards contraception found that the need for a prescription (28%) and general practitioner (GP) costs (20%) were barriers, and 54% of women chose their contraception method because it did not require a prescription [8] .
Removing the prescription requirement may also increase contraception continuation [9] .
The Australian Therapeutic Goods Administration (TGA) committee rejected reclassifying a range of OCPs from prescription-to pharmacist-only medicines in 2015 [10] . Deliberations focused on safety concerns, such as stroke and venous thromboembolism (VTE), and the reduced use of other contraceptive methods, such as long-acting reversible contraceptives (LARCs). 1 The committee did not appear to consider, or placed less importance on, pregnancies, and thus abortions and miscarriages, and their associated healthcare resource use (e.g. GP visits), which could be used to treat other patients.
Medsafe in New Zealand reclassified selected OCPs to make them available directly through specially trained pharmacists in 2017, although women aged less than 16 years and first time users were ineligible [11] . Only an initial prescription is required in the Netherlands and refills may be purchased from a pharmacy indefinitely thereafter [12] . In Oregon and California in USA, women can purchase The model had 18 health states, including: never had sex; trying to conceive (TTC); contraceptive method 2 by year of use, whether previously pregnant; and dead. The first year of use was modelled separately to later years as pregnancies and discontinuations/switches are more common in the first year. Transitions included: sexual debut; pregnancies; initiating contraception, discontinuing contraception, switching contraceptive methods; and death. Women may initiate, discontinue, or switch their contraceptive method up to three times prior to pregnancy, and four times following pregnancy. The contraceptive method chosen was determined by the woman's age, whether previously pregnant, and whether OCPs are reclassified to pharmacist-only. Pregnancy outcomes, adverse events (AEs), and sexually transmitted infections (STIs) were temporary health states. Deaths may occur as a result of AEs, ovarian cancer, pregnancy complications, or other causes (age-related mortality). The cycle length was 1 year. The model time horizon was 35 years, reflecting the difference between the age of the youngest and oldest cohorts and to capture the long-term effect on health outcomes.
It was assumed that:
• Levels of sexual activity are not influenced by the availability of pharmacist-only OCPs.
• One pregnancy can occur per year.
• AEs occur during the first year of contraceptive use, reflecting that research largely reported AE incidence per patient, not per patient year, and many occur during the first year [28] .
• STIs can occur every year.
• Women can use up to two different types of contraceptives simultaneously (i.e. condoms plus another method).
• It is not possible to discontinue male or female sterilisation.
The analysis was from the Australian healthcare system perspective (costs incurred by patients, the government and private healthcare providers) and a 5% discount rate was applied to both costs and QALYs, to ensure consistency with other decision-making bodies of the Australian Government Department of Health [29] . The analysis was conducted in Microsoft Excel (2013). All parameters used in the economic model, the Consolidated Health Economic Evaluation Reporting Standards statement and the Assessment of the Validation Status of Health-Economic decision models checklist are provided in the Electronic Supplementary Material (ESM) [30, 31] .
Contraceptive Use
The proportion of women who had ever had sex was based on the Second Australian Study of Health and Relationships (N = 20,094) [25] , and the proportion of women TTC was based on data from the Australian Bureau of Statistics [32] . Women who have had sex and were not TTC may use a range of contraceptive methods or none. Current patterns of contraceptive use by age and whether previously pregnant were based on Wave 15 (2015) of the Household, Income and Labour Dynamics in Australia (HILDA) survey (N = 4755), a large, nationally representative longitudinal survey [7] . OCPs can either be the progestin-only pill (POP) or, more commonly, the combined oral contraceptive (COC) pill, which includes progestin and oestrogen. Unfortunately, HILDA did not report women using POP vs. COC separately, and thus the results were reported for OCPs as a whole. Women who have never had sex, aged less than 15 years, TTC, or aged 50 years and over were assumed to not use contraception. As 56.5% of women aged 15-19 years use contraception, it was assumed that 10% of women initiate contraception per year from 15 to 19 years of age [7] . Table 1 provides the switch rates to pharmacist-only OCPs. These rates were largely based on a US online survey, which estimated the likelihood of using over-the-counter OCPs among low-income adult women at risk of unintended pregnancy given their current contraceptive method of choice (N = 879) [21] . It was assumed that women who were "very likely to use over-the-counter OCPs" would switch from their current contraceptive method (including It was also assumed that women who have never had sex, aged 50 years or more, TTC, or using female or male sterilisation would not switch to pharmacist-only OCPs. Furthermore, it was assumed that women using condoms plus prescription OCPs would switch to using condoms plus pharmacist-only OCPs, thus remain protected against STIs, while all other women would switch to using pharmacistonly OCPs alone even if using condoms (e.g. condoms plus withdrawal). Consequently, condom use was assumed to decrease following reclassification.
Annual contraceptive discontinuation or switch rates were based on the 1995 US National Survey of Family Growth (N = 6867) [33] and the 2007 Contraceptive CHOICE project (N = 9256) [34] , with higher discontinuation and switch rates in the first year. Providing OCP users with more packs and removing the prescription requirement leads to increased continuation [35] . Consequently, an odds ratio (0.759) of discontinuing or switching pharmacist-only OCPs was estimated, based on a study comparing US women obtaining OCPs in family planning clinics in El Paso, Texas, to women obtaining OCPs at a pharmacy across the border in Mexico, after controlling for confounders [9] .
Pharmacist Behaviour
AEs can be mitigated through the use of an OCP Questionnaire, which screens women for potential contraindications, underlying health conditions, family history of disease and blood pressure. No OCP Questionnaire currently exists for the Australian context, but if introduced, is likely to be similar to that currently used in New Zealand [36] , or to the patient group direction for community pharmacists to supply the OCP without a prescription piloted in the UK [37] . It was estimated that pharmacists would supply pharmacist-only OCPs to 91.4% of women requesting pharmacist-only OCPs, based on the UK pilot study [37] . Other women would be required to obtain a prescription. The pilot study also found that pharmacists made clinically appropriate supplies and referred correctly in all cases reviewed. Consequently, it was assumed that the OCP Questionnaire would mitigate any additional risk of AEs with pharmacist-only OCPs (odds ratio = 1). A threshold analysis was conducted on the odds ratio of the risk of AEs with pharmacist-only OCPs.
Pharmacists could also use the OCP Questionnaire to counsel women about preventing STIs with condoms, and may increase referrals to GPs regarding other medical concerns. These benefits and costs were not considered in the model.
Health Outcomes
Pregnancy rates were based on the National Survey of Family Growth study (N = 6867) [33] . Effectiveness in later years was estimated as the difference in pregnancy rates at 2 years compared with 1 year. The comparative effectiveness of POP and COC is uncertain, and thus were assumed to be similar [38] . The comparative effectiveness of prescription-only OCPs and pharmacist-only OCPs were also assumed to be similar.
Pregnancies may result in a live birth, miscarriage, stillbirth, ectopic pregnancy or an abortion. Pregnancy outcomes, including deaths, were based on data from the Australian Bureau of Statistics [32] and the Australian Institute for Health and Welfare [39] . A systematic review and meta-analysis found that OCPs reduce the likelihood of ovarian cancer by 27%. [40] Australian cancer registry data informed baseline ovarian cancer risk by age [41] and mortality per case [42] . As there is limited evidence regarding the impact of other hormonal methods on ovarian cancer, [43] it was assumed that all hormonal methods have a similar impact on ovarian cancer. Other additional benefits from OCPs (e.g. decreased risk of endometrial cancer) were not included because of a lack of data [44, 45] . Age-specific natural mortality was based on life tables from the Australian population [46] .
Adverse Events
Common minor AEs with OCPs include headache, breast tenderness, bleeding irregularities, nausea and decreased libido, while less common AEs include mild depression, VTE, myocardial infarction and stroke [28, [47] [48] [49] [50] . These latter AEs were considered by the TGA committee [10] . Published systematic reviews and large observational studies informed rates of depression, VTE, myocardial infarction and stroke risk with hormonal contraceptives [28, [48] [49] [50] . AEs were not differentiated by whether a POP or COC was used as no data were available on the type of OCP that women used in HILDA [7] . Breast cancer risk with OCPs was not included as a recent large observational study (N = 1,083,000) found no significant breast cancer risk with OCPs (relative risk 0.98, 95% confidence interval 0.87-1.10) [51] . AEs associated with other contraceptives, such as perforation with intrauterine devices (IUDs), were not included.
Sexually Transmitted Infections
The TGA committee did not consider increased STI risk from decreased condom use if pharmacist-only OCPs were available [10] . The condom is the only contraceptive method that reduces STIs. It was estimated that condoms were 80% effective against human immunodeficiency virus transmission, based on a Cochrane systematic review [52] . Similar effectiveness of condoms against other STIs was assumed [53] . Australian surveillance data informed the risk of STIs and high-grade cervical abnormalities [54] [55] [56] . The latter may be an overestimate as the Australian human papillomavirus vaccination programme is likely to reduce the risk of human papillomavirus considerably in the future [57] .
Utilities
QALYs were estimated based on the population norm utilities corresponding with the woman's age [58] and the disutilities associated with pregnancy outcomes, ovarian cancer, AEs and STIs were based on the published literature [24, [59] [60] [61] [62] [63] [64] . The impact of ovarian cancer on QALYs was informed by a prospective observational study of Australian patients [65] . A lifetime loss of 4.45 QALYs was applied for human immunodeficiency virus cases to account for the complex disease pathway, based on a published study [66] . No disutilities associated with stillbirth were identified, and thus no disutilities were applied in the base case.
Resource Use
GP consultations to obtain OCP prescriptions were estimated for each contraceptive method, taking into account the pack size and repeats [67] . Around 1.551 problems are discussed per GP consultation, based on the Bettering the Evaluation and Care of Health (BEACH) program [68] . Consequently, it was estimated that for every prescription avoided by reclassifying OCPs, 64.5% of GP consultations are avoided (1/1.551).
Condom use was based on intercourse frequency by age, assuming one condom per encounter, based on a UK study (N = 15,162) [69] . Information from the TGA and Family Planning NSW informed the frequency of use of other contraceptives (and thus GP/specialist consultations) [70] [71] [72] [73] [74] [75] .
Pharmacist time to counsel women and dispense a prescription medicine was estimated to be 2 min, based on Australian and US surveys [76, 77] . Pharmacist time to supply pharmacist-only OCPs was estimated to be 20 min [78] . It was estimated that training to use the OCP questionnaire would take 5 h per pharmacist and two thirds of pharmacists would participate in training [79] . Healthcare resource use related to pregnancies, AEs and STIs were based on published Australian government documents, Australian studies, treatment guidelines and expert opinion (see the ESM).
Unit Costs
All costs were reported in 2016 Australian Dollars (A$) [A$1 = US$0.7133 on 7 January 2019] [80] . Stroke healthcare costs were based on data from the Australian Institute for Health and Welfare, while myocardial infarction and ovarian cancer costs were based on published prospective observational studies of Australian patients, inflated to 2016 values [65, [81] [82] [83] . Unit costs associated with other types of resource use were based on standard government sources and the published literature (see the ESM). It was assumed that the unit cost of contraceptives would be unchanged by reclassification.
Reporting of Results and Sensitivity Analyses
The analysis was conducted for each 1-year age group in the cohort of women aged 15-49 years, which was then summed to estimate the total impact on health outcomes and costs. Disaggregated results were also presented. Univariate sensitivity analyses were conducted on all parameters by varying each parameter to the upper and lower 95% confidence intervals (see the ESM).
Scenario analyses were conducted by varying each parameter to a pre-specified level. In particular, a scenario analysis was conducted on removing the need to obtain a prescription from a GP before using pharmacist-only OCPs, which involved removing the cost of the initial GP visit and assuming that pharmacists would initially supply pharmacist-only OCPs to 91.4% of women (rather than 100%). A scenario analysis was also conducted on the effectiveness of pharmacist-only OCPs, which may improve rates of perfect use (e.g. using every day) of OCPs owing to the removal of the need for urgent GP appointments when patients lose prescriptions or exhaust their supply of medicine [8, 9, 84] . Consequently, the effectiveness of pharmacist-only OCPs was estimated as the average of the effectiveness of OCPs with typical use and perfect use (e.g. pregnancy rates of 9% in the first year vs. 0.3% in the first year) [85] , resulting in improved effectiveness (4.7%) compared with prescriptiononly OCPs (6.9%) [33] .
A scenario analysis was also conducted on health outcomes following stillbirth by applying an assumed 10 QALYs lost per stillbirth, as per an assumption by the UK's National Institute for Health and Care Excellence [86] . In the base case, future QALYs that would have been experienced by unborn children were excluded. A scenario analysis was also conducted where QALYs lost were estimated by applying population norm utilities by age to life expectancy at birth [46, 58] .
Threshold analyses were conducted by varying a parameter value until an incremental cost-effectiveness ratio (ICER) of A$60,000/QALY gained was reached. This ICER is the midpoint of the range ($45,000-$75,000/QALY gained) often quoted by the Australian Pharmaceutical Benefits Advisory Committee as being acceptable for funding [87] . The TGA does not have a threshold for assessing whether reclassifying a medicine is cost effective, as this approach has not been previously applied. The TGA committee, through the OCP Questionnaire, could vary the lower or upper age limit on access. Consequently, a sub-group analysis was also conducted on the initial age of women.
A probabilistic sensitivity analysis was conducted using Monte Carlo simulation methods to explore the uncertainty surrounding the ICER (10,000 iterations). A method of moments approach was used to fit the distributions based on the mean and standard error of the estimates. Unit costs were assumed to be certain, except for stroke, myocardial infarction and ovarian cancer costs.
Model Calibration and Validation
Women TTC was not reported by age and no data were available on pregnancy rates by women not TTC. These variables were estimated by calibrating the model such that the number of births per woman equalled that from the Australian Bureau of Statistics (1.789) [88] . Face validity of the model structure and results was tested with two medical practitioners and a pharmacist. External validity was tested by comparing the predicted age of mothers in the model (30.45 years) to that in Australia (31.2 years) [88] . Further information is available in the Assessment of the Validation Status of Health-Economic decision models checklist provided in the ESM. Following OCP reclassification, women would also experience fewer miscarriages, abortions, ectopic pregnancies, stillbirths and ovarian cancer cases. However, STIs would increase as a result of reduced condom use, and AEs associated with OCPs would also increase. Overall, there would be 22 fewer deaths over 35 years. Table 3 presents the estimated discounted QALYs gained in the base case. Reclassifying OCPs would result in a net gain of 17,159 QALYs over 35 years, or 0.003 QALYs per woman aged 15-49 years. QALYs will be mainly gained from fewer pregnancies, as fewer women would use less effective or no contraceptive methods but some QALYs will be lost as a result of AEs and STIs. Table 4 presents the estimated discounted costs incurred in the base case. Reclassifying OCPs will save A$3365 million over 35 years (A$96 million per annum). This equates to A$596 per woman aged 15-49 years (A$17 per annum per woman). This was largely driven by a reduction in the cost of live births, rather than GP/specialist costs. Conversely, contraceptive costs will increase as women switch from less expensive contraceptive methods (none or condoms) to pharmacist-only OCPs, and pharmacist costs will increase as pharmacists spend more time counselling women. Overall, reclassifying OCPs to pharmacist-only would result in a net gain in QALYs and cost savings (see Table 5 ).
Results

Base-Case Results
Sensitivity Analysis
Univariate sensitivity and scenario analyses indicated that results were most sensitive to the probability of pregnancy when not using contraception and not TTC (see Fig. 4 and the ESM). When this variable was set to the lower bound of the 95% confidence interval, reclassification was more costly and resulted in fewer QALYs. The scenario analysis found that the results were most sensitive to including future QALYs lost from unborn children (reclassifying OCPs would result in fewer QALYs and would not be cost effective). Shortening the time horizon to 5 years reduced the QALYs gained (8567 QALYs) but reclassifying OCPs remained cost saving. While excluding utilities associated with pregnancy outcomes resulted in 846 fewer QALYs, the net benefit (using a threshold of A$60,000/QALY gained) remained positive owing to large cost savings from reduced healthcare resource use associated with reduced pregnancies. Finally, if the QALYs gained from a reduction in stillbirths were included, it was estimated that reclassifying OCPs will result in 49,048 QALYs gained over 35 years, or 0.009 QALYs per woman.
The sub-group analysis indicated that reclassification will result in health gains and be cost saving for all age groups; however, the benefits reduced with increasing age and approached nil as the woman's age approached 45 years, reflecting a reduced pregnancy rate and an increased risk of AEs (see Fig. 5 ). However, the threshold analysis found that the odds ratio of experiencing an AE (depression, VTE, stroke and myocardial infarction) with OCP reclassification to pharmacist-only compared with OCPs remaining prescription only needed to be 14 or more for reclassification to have an ICER greater than A$60,000/QALY gained. In the base case, it was assumed that the odds ratio equalled one. Finally, the probabilistic sensitivity analysis indicated that OCP reclassification had an estimated 95% probability of being cost effective at a threshold of A$60,000/QALY gained (see Figs. 6 and 7).
Discussion
Economic modelling suggests that reclassifying OCPs to pharmacist-only will prevent unintended pregnancies, result in net health gains, and is likely to be considered cost effective by decision makers in Australia using a A$60,000/ QALY gained threshold. It was assumed that women must first consult a GP and receive a prescription for an OCP, and thereafter pharmacists would use the OCP Questionnaire at each subsequent request for OCPs. The QALYs gained from reclassification were mainly through avoided pregnancies and the cost savings were mainly from fewer live births. This suggests the results were largely driven by fewer women using less effective contraceptive methods.
The Australian Government has explored measures such as prescriptions with 12 months' supply of OCPs per prescription and continued supply of OCPs where Pharmaceutical Benefits Scheme-subsidised OCPs can be supplied without a prescription conditional on a clinical review by a GP in the past 12 months, there is immediate need and it is not practicable to obtain a prescription [89] . However, the latter has been of limited value to women, as each prescription covers 12 months' supply, and few use Pharmaceutical Benefits Scheme-listed OCPs [56] .
The TGA committee rejected OCP reclassification to pharmacist-only mainly because of safety concerns [10] . Economic modelling was not undertaken to inform the decision. At that time, there was no facility to enable mandatory training and screening tool use in pharmacy, but now this is possible [90] .
The model included several health outcomes considered by the TGA committee, such as ovarian cancer, depression, More effective and cost saving VTE, myocardial infarction and stroke. The model also included evidence that did not appear to be considered by the TGA committee, such as the rate of switching from a wide variety of different contraceptives and their effectiveness, pregnancy rates, STIs, and the impact on healthcare resources, including GP and pharmacist time and hospitalisations. These healthcare resources could be used to treat other patients leading to improved health outcomes. The impact on healthcare resources other than GPs were not considered by the TGA.
The approach and results generated insights that the TGA committee may have considered valuable. The base-case analysis indicated that LARC use will decrease, contrary to recent policy initiatives aiming to increase LARC use [91] . Pregnancy and discontinuation rates are lower with LARCs compared with OCPs [33, 34] . Consequently, reclassifying OCPs could have resulted in fewer QALYs owing to reduced use of LARCs. Instead, reclassifying OCPs increased QALYs as a small proportion of women currently use LARCs in Australia (23.2%) and the estimated switch rate from LARCs to pharmacist-only OCPs was lower, [36] . AE risk may increase with OCP reclassification to pharmacist-only as a result of women not fully discussing their medical history or pharmacists not following the OCP Questionnaire. Pharmacist-only OCPs may also mask or delay the diagnosis of AEs, such as endometrial cancer or polyps, although OCPs are also associated with a decreased risk of endometrial cancer [44, 45] . However, threshold analysis found that the odds ratio of experiencing an AE must be 14 or more for reclassification to have an ICER more than A$60,000/QALY gained. Furthermore, the sub-group analysis found that the benefits reduced with increasing age, suggesting that the TGA committee may consider restricting pharmacist-only OCPs from older women through the OCP questionnaire.
Results from the sensitivity analysis suggest that more research is needed regarding pregnancy rates in women not using contraceptives and not TTC. Finally, a scenario analysis found that reclassification would result in a net QALY loss if future QALYs from unborn children were included.
Excluding future QALYs from unborn children is common practice [92] ; however, the decision to exclude these QALYs is a policy decision. A scenario analysis was conducted in the interest of transparency.
A key strength of this study was that it explored the impact of OCP reclassification over a 35-year period, which enabled the incorporation of different contraceptive use patterns depending on the woman's lifecycle, different pregnancy rates over time, and different AEs and STIs risks over time. Previous evaluations have found that OCP reclassification is cost effective [20] [21] [22] [23] . Koslow et al. [22] conducted a cost analysis of reclassifying OCPs in Australia; however, they only considered the impact on GP consultations, assumed a one-to-one relationship between OCP prescriptions and GP visits avoided, and did not take into account the impact on health outcomes. That evaluation estimated that savings from reduced GP consultations from reclassifying OCPs was in excess of A$90 million per annum-much larger than this evaluation (A$2 million per annum), which did not assume that all GP visits involving an OCP prescription would be avoided. Zhu et al. [20] also conducted a cost analysis of reclassifying OCPs in USA from the societal perspective and estimated that reclassifying OCPs would Fig. 6 Cost-effectiveness plane comparing pharmacist-only oral contraceptive pills available with prescription-only oral contraceptive pills (10,000 iterations) Fig. 7 Incremental costeffectiveness acceptability curve (10,000 iterations). OCPs oral contraceptive pills, QALY quality-adjusted life year result in US$12.6 billion in savings annually (US$201 per woman)-much larger than this study (A$17 per annum per woman). However, that evaluation also assumed contraceptive prices would decrease after reclassification as a result of increased competition. In contrast, this evaluation assumed prices would remain the same. Mead [23] conducted a costconsequences analysis and considered a wide range of health outcomes and AEs, although did not aggregate these into a single measure. That evaluation also estimated the impact on resource use and productivity costs. Overall, that evaluation estimated that reclassification would be cost saving; however, the estimate included increased revenue for manufacturers as a benefit. Removing this benefit would result in reclassification being marginally costlier. Finally, Foster et al. [21] conducted a cost analysis of reclassifying OCPs in USA from the societal perspective, but did not include AEs and STIs. Foster et al. estimated that pregnancies would fall 11-18% making reclassifying OCPs cost saving, which is higher than this evaluation (8.3%).
Our analysis has some limitations. One is the lack of data regarding the proportion of women TTC by age and the probability of pregnancy for women not using contraceptives and TTC, which were estimated by calibrating the model. Assumptions were also required for some model inputs because of a lack of data, such as the use and effectiveness of POPs vs. COCs, the duration of symptoms for AEs and increased AE risk with pharmacist-only OCPs. Switch rates to pharmacist-only OCPs were based on a US survey of low-income women, which did not require women to visit a GP prior to initiating OCPs [21] . The applicability of these data to Australia is uncertain, and dependent upon several factors such as the need for an initial GP consultation, the cost of contraceptives and GP consultations, and GP accessibility. However, it was the only study identified that estimated switch rates by current contraceptive use. The univariate analysis found that the results were only somewhat sensitive to changes in the switch rates. Further research is needed regarding the likely behaviour of women following OCP reclassification in Australia, including switch rates, condom use and STI screening. The development of an Australian OCP Questionnaire would also be needed, accompanied by a validation study comparing the supply of pharmacist-only OCPs with GP prescription of OCPs to women with different levels of risk of AEs. Similarly, the odds ratio of discontinuing or switching pharmacist-only OCPs was also based on a US study, and the results may also not be applicable to Australia for similar reasons as per switch rates. The baseline risk of STIs, myocardial infarction and stroke were based on the general population, and thus may have been overestimated as some women would have been using condoms or OCPs. This study also did not consider the costs to women or employers for taking time off work to attend doctors' consultations vs. visiting a pharmacy only, nor the cost and time associated with travel. There may be productivity and travel cost savings for society from OCP reclassification to pharmacist-only, in addition to cost savings for the healthcare system. Finally, the aim of this study was to demonstrate the advantages of applying economic modelling to reclassification decisions, and thus other potential comparators such as 36 months' supply of OCPs were not considered.
Conclusion
Reclassifying OCPs to pharmacist-only is likely to result in net health gains and be cost saving, even after including the impact on a broad range of risks from reclassifying OCPs, including STIs and AEs. However, the benefits reduce with increasing age. More research is needed regarding pregnancy rates in women not using contraceptives and not TTC. This study demonstrated that economic modelling may be valuable for regulatory decisions regarding access to medicines, and could provide valuable insights to decision makers regarding areas in need of further research and regulatory options.
